Johnson & Johnson (JNJ)vsProtagonist Therapeutics Inc (PTGX)
JNJ
Johnson & Johnson
$275.19
+1.53%
HEALTHCARE · Cap: $615.87B
PTGX
Protagonist Therapeutics Inc
$142.14
+0.72%
HEALTHCARE · Cap: $8.33B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 35126% more annual revenue ($99.33B vs $281.99M). PTGX leads profitability with a 29.4% profit margin vs 16.2%. JNJ trades at a lower P/E of 38.8x. PTGX earns a higher WallStSmart Score of 63/100 (C+).
JNJ
Buy57
out of 100
Grade: C
PTGX
Buy63
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-83.0%
Fair Value
$144.12
Current Price
$275.19
$131.07 premium
Intrinsic value data unavailable for PTGX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 25.1%
Generating 6.4B in free cash flow
Strong operational efficiency at 74.4%
Revenue surging 3749.0% year-over-year
Earnings expanding 351.3% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Keeps 29 of every $100 in revenue as profit
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Expensive relative to growth rate
Earnings declined 96.0%
Trading at 10.9x book value
Weak financial health signals
Premium valuation, high expectations priced in
ROE of -17.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 25.1%.
Bull Case : PTGX
The strongest argument for PTGX centers on Operating Margin, Revenue Growth, EPS Growth. Profitability is solid with margins at 29.4% and operating margin at 74.4%. Revenue growth of 3749.0% demonstrates continued momentum.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, Piotroski F-Score, PEG Ratio.
Bear Case : PTGX
The primary concerns for PTGX are Price/Book, Piotroski F-Score, P/E Ratio. A P/E of 125.0x leaves little room for execution misses.
Key Dynamics to Monitor
JNJ profiles as a mature stock while PTGX is a growth play — different risk/reward profiles.
PTGX carries more volatility with a beta of 1.52 — expect wider price swings.
PTGX is growing revenue faster at 3749.0% — sustainability is the question.
JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.
Bottom Line
PTGX scores higher overall (63/100 vs 57/100), backed by strong 29.4% margins and 3749.0% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Protagonist Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. The company is headquartered in Newark, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?